Monday December 10, 2018

Hour-long afternoon naps may increase risk of diabetes: Study

0
//
Republish
Reprint

London: While taking a short nap may be good for your health, extending it to an hour or more significantly increases risk of developing diabetes, says a new study. “Excessive daytime sleepiness and taking longer naps were associated with increased risk of Type-2 diabetes, with a short nap not increasing this risk,” the study said.

Woman-sleeping-in-bed-560500
www.express.co.uk

The research by Tomohide Yamada from University of Tokyo in Japan analysed studies published till November 2014 on the association between daytime sleepiness, nap, and diabetes. After examining over 600 hundred studies including 261,365 people from Asian and Western countries, the research found that excessive daytime sleepiness increased the risk of diabetes by 56 percent, while a longer daytime nap of 60 minutes or more increased the risk by 46 percent. In contrast, a shorter nap (60 mins or less per day) did not increase the risk of diabetes.

The analysis showed there was no effect of napping up to about 40 minutes per day, after which risk began to increase sharply. “Daytime napping might be a consequence of night-time sleep disturbance such as obstructive sleep aponea (OSA), the study noted. Several studies have demonstrated the beneficial effects of taking short naps less than 30 minutes in duration, which help to increase alertness and motor skills. “A short nap finishes before the onset of deep slow-wave sleep.

“Entering deep slow-wave sleep and then failing to complete the normal sleep cycle can result in a phenomenon known as sleep inertia, in which a person feels groggy, disoriented, and even sleepier than before napping” Dr Tomohide Yamada said.

“Although the mechanisms by which a short nap might decrease the risk of diabetes are still unclear, such duration-dependent differences in the effects of sleep might partly explain our findings,” Yamada noted. The findings were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.

(IANS)

Click here for reuse options!
Copyright 2015 NewsGram

Next Story

New Drug Offers Treatment For Diabetes-Related Blindness

The researchers now plan to conduct a full-scale clinical trial, Gamble said

0
new policy will see the launch of 12 programmes relevant to private schools across the emirate
New drug offers hope for diabetes-related blindness.

In a major breakthrough, Australian scientists have developed a new drug that offers treatment for people suffering from diabetic retinopathy — the main cause of blindness from diabetes.

The debilitating disease occurs when tiny blood vessels in the retina, responsible for detecting light, leak fluid or haemorrhage.

While treatment options include laser surgery or eye injections of anti-vascular endothelial growth factor (VEGF), they are not always effective or can result in side effects, highlighting the need for alternative therapeutic approaches.

The team from the Centenary Institute in Sydney developed a novel drug CD5-2, which in mouse models was found to mend the damaged blood retinal barrier and reduce vascular leakage.

“We believe CD5-2 could potentially be used as a stand-alone therapy to treat those patients who fail to respond to the anti-VEGF treatment. It may also work in conjunction with existing anti-VEGF treatments to extend the effectiveness of the treatment,” said lead author Ka Ka Ting from the Institute.

“With limited treatment options currently available, it is critical we develop alternative strategies for the treatment of this outcome of diabetes,” Ting added.

Diabetes
Representational image. Pixabay

The key process involved in diabetic retinopathy pathology is the breakdown of the blood-retinal barrier (BRB), which is normally impermeable. Its integrity relies on how well capillary endothelial cells are bound together by tight junctions. If the junctions are loose or damaged, the blood vessels can leak.

In the study, reported in the journal Diabetologia, CD5-2 was found to have therapeutic potential for individuals with vascular-leak-associated retinal diseases based on its ease of delivery and its ability to reverse vascular dysfunction as well as inflammatory aspects in animal models of retinopathy.

Previous studies have shown that CD5-2 can have positive effects on the growth of blood vessels.

Also Read- Facebook Invests $1 mn To Boost Computer Science Education

“This drug has shown great promise for the treatment of several major health problems, in the eye and in the brain,” said Professor Jenny Gamble, head of Centenary’s Vascular Biology Programme.

The researchers now plan to conduct a full-scale clinical trial, Gamble said. (IANS)